earnings
confidence high
sentiment neutral
materiality 0.50
Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3
Acurx Pharmaceuticals, Inc.
2024-Q3 EPS reported
-$0.71
- Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.
- Cash $5.8M at Sep 30, 2024, down from $7.5M at Dec 31, 2023; raised $1.6M gross via ATM.
- Requested FDA CMC meeting to start Phase 3 for ibezapolstat; USPTO patent granted through 2042.
- R&D expenses $1.2M (Q3) vs $1.3M prior year; G&A $1.6M vs $1.8M prior year.